MORRIS PLAINS, N.J., July 15, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that it was awarded US patent 7,560,110, "Production and use of novel peptide-based agents with bispecific antibodies." This patent covers both constructs and methods of use for bispecific antibodies or antibody fragments, for use in the technology called 'pretargeting,' which Immunomedics and its subsidiary, IBC Pharmaceuticals, Inc., have in preclinical and clinical development for cancer imaging and therapy. The technology not only includes treatment of cancers, but also other diseases, such as infectious diseases (e.g., bacterial, fungal, viral, and protozoan infections), as well as imaging of normal and diseased organs. It includes diverse molecular imaging methods, such as nuclear (SPECT and PET), fluorescence, ultrasound, and magnetic resonance imaging. Therapeutically, the patent covers pretargeting with radionuclides, drugs, prodrugs and toxins.
